Product Description
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteosarcoma|Leiomyosarcoma|Primitive Neuroectodermal Tumors|Sarcoma, Ewing|Rhabdomyosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Prostate Cancer|Synovial Sarcoma|Adrenocortical Carcinoma|Adenocarcinoma|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Male Breast Cancer|Uveal Melanoma|Pancreatic Cancer|Hepatocellular Carcinoma|Small Cell Lung Cancer|Breast Cancer|Large Cell Carcinoma|Liposarcoma|Esophageal Cancer|Gliosarcoma|Neurofibrosarcoma|Neuroendocrine Tumors|Embryonal Rhabdomyosarcoma|Colorectal Cancer|Gastrointestinal Cancer|Hemangiosarcoma|Alveolar Soft Part Sarcoma|Bronchiolo-Alveolar Adenocarcinoma|Alveolar Rhabdomyosarcoma|Neuroendocrine Carcinoma|Liver Cancer|Mesothelioma|Peritoneal Cancer|Embryonal Carcinoma|Hepatoblastoma|Wilms Tumor|Kidney Cancer|Soft Tissue Cancer|Neuroblastoma|Retinoblastoma
Phase 1: Oncology Solid Tumor Unspecified|Somatostatinoma|Carcinoma, Merkel Cell|Islet Cell Carcinoma|Paraganglioma|Hepatocellular Carcinoma|Carcinoid Tumor|Medullary Carcinoma|Carotid Body Tumor|Neuroendocrine Tumors|Neuroendocrine Carcinoma|Gastrointestinal Cancer|Insulinoma|Glucagonoma|Pancreatic Cancer|Malignant Carcinoid Syndrome|Neutropenia|Pinealoma|Glioma|Gastrinoma|Hyperglycemia|Thrombocytopenia|Hypertension|Anemia|Sarcoma, Ewing|Peripheral Neuroectodermal Tumors, Primitive|Primitive Neuroectodermal Tumors
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01008566 |
NCI-2012-03186 | P1 |
Completed |
Hepatocellular Carcinoma |
2016-05-01 |
2019-03-19 |
Treatments |
|
NCT01204476 |
NCI-2010-02196 | P1 |
Completed |
Gastrinoma|Malignant Carcinoid Syndrome|Pancreatic Cancer|Glucagonoma|Insulinoma|Carotid Body Tumor|Medullary Carcinoma|Carcinoid Tumor|Paraganglioma|Islet Cell Carcinoma|Carcinoma, Merkel Cell|Gastrointestinal Cancer|Neuroendocrine Carcinoma|Neuroendocrine Tumors|Somatostatinoma |
2014-07-01 |
2019-03-19 |
Treatments |
|
NCT00678769 |
NCI-2009-00282 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-06-01 |
2019-03-18 |
Treatments |
|
NCT01061749 |
NCI-2012-02912 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2013-04-01 |
2019-03-19 |
Treatments |
|
NCT01007032 |
CP13-0813 | P1 |
Completed |
Hypertension|Thrombocytopenia|Anemia|Neutropenia|Hyperglycemia |
2012-12-01 |
2019-03-19 |
Treatments |
|
NCT00880282 |
NCI-2011-01910 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2012-10-01 |
2019-03-18 |
Treatments |
|
NCT00957853 |
NCI-2011-03039 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2018-08-15 |
50% |
2019-03-18 |
|
NCT01263782 |
BATTLE-FL | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-08-15 |
2019-03-19 |
Treatments |
|
NCT00887159 |
NCI-2011-01917 | P2 |
Completed |
Small Cell Lung Cancer |
2016-11-15 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT01160458 |
10-C-0146 | P2 |
Completed |
Mesothelioma|Peritoneal Cancer |
2016-08-13 |
2019-03-19 |
Treatments |
|
2010-024014-60 |
A Study in Non-Small Cell Lung Cancer | P2 |
Completed |
Squamous Cell Carcinoma |
2016-06-10 |
2022-03-13 |
Treatments |
|
NCT01055314 |
NCI-2011-02005 | P2 |
Completed |
Alveolar Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma |
2016-06-01 |
2024-11-27 |
||
NCT00955305 |
NCI-2011-01960 | P2 |
Terminated |
Large Cell Carcinoma|Non-Small-Cell Lung Cancer|Bronchiolo-Alveolar Adenocarcinoma |
2016-01-01 |
2019-03-18 |
Treatments |
|
NCT01120236 |
NCI-2011-02003 | P2 |
Completed |
Prostate Cancer|Adenocarcinoma |
2015-06-01 |
2019-03-19 |
Treatments |
|
NCT01142388 |
NCI-2011-02045 | P2 |
Active, not recruiting |
Adenocarcinoma|Squamous Cell Carcinoma|Esophageal Cancer|Gastrointestinal Cancer |
2014-07-15 |
2024-04-03 |
Primary Endpoints|Study Completion Date|Treatments |
|
NCT01016015 |
NCI-2011-01408 | P2 |
Completed |
Osteosarcoma |
2014-07-01 |
2019-03-19 |
Treatments |
|
NCT01614795 |
NCI-2012-01971 | P2 |
Completed |
Primitive Neuroectodermal Tumors|Synovial Sarcoma|Gliosarcoma|Alveolar Soft Part Sarcoma|Leiomyosarcoma|Embryonal Rhabdomyosarcoma|Osteosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Neurofibrosarcoma|Sarcoma, Ewing|Hemangiosarcoma|Alveolar Rhabdomyosarcoma|Liposarcoma |
2014-04-01 |
2019-03-19 |
Treatments |
|
NCT00684983 |
NCI-2009-00665 | P2 |
Completed |
Breast Cancer |
2014-01-07 |
2023-04-20 |
Primary Endpoints|Treatments |
|
NCT00699491 |
NCI-2009-00284 | P2 |
Completed |
Male Breast Cancer |
2013-09-09 |
2019-03-22 |
Treatments |
|
NCT00986674 |
NCI-2011-01976 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2013-08-01 |
2019-03-19 |
Treatments |
|
2010-022674-14 |
2010-022674-14 | P2 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma |
2013-05-09 |
2022-03-13 |
Treatments |
|
NCT00831844 |
NCI-2009-01170 | P2 |
Completed |
Hepatoblastoma|Embryonal Rhabdomyosarcoma|Wilms Tumor|Retinoblastoma|Liver Cancer|Soft Tissue Cancer|Embryonal Carcinoma|Synovial Sarcoma|Peripheral Neuroectodermal Tumors, Primitive|Adrenocortical Carcinoma|Neuroblastoma|Kidney Cancer|Osteosarcoma|Sarcoma, Ewing|Primitive Neuroectodermal Tumors |
2013-04-01 |
2019-03-18 |
Treatments |
|
NCT01413191 |
NCI-2011-02228 | P2 |
Completed |
Uveal Melanoma |
2013-03-01 |
2019-03-19 |
Treatments |
|
NCT01026623 |
NCI-2011-01406 | P2 |
Completed |
Prostate Cancer|Adenocarcinoma |
2013-02-01 |
2019-03-19 |
Treatments |
|
NCT01232452 |
I5A-MC-JAEM | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2013-01-01 |
2019-03-19 |